ARS Pharmaceuticals (SPRY) EBITDA (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of EBITDA data on file, last reported at -$60.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 61.78% year-over-year to -$60.1 million; the trailing twelve-month figure through Mar 2026 stood at -$202.4 million (down 647.81% YoY), and the FY2025 full-year result was -$179.4 million, down 5720.56% from the prior year.
• EBITDA slipped to -$60.1 million in Q1 2026, from -$41.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $47.2 million in Q4 2024 to a low of -$60.1 million in Q1 2026.
• A 5-year average of -$20.3 million and a median of -$18.0 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 224.76% in 2023 and surged 561.54% in 2024, its largest moves.
• Tracing SPRY's EBITDA over 5 years: stood at -$15.4 million in 2022, then surged by 33.78% to -$10.2 million in 2023, then surged by 561.54% to $47.2 million in 2024, then sank by 187.86% to -$41.5 million in 2025, then sank by 45.05% to -$60.1 million in 2026.
• Business Quant data shows SPRY's EBITDA at -$60.1 million in Q1 2026, -$41.5 million in Q4 2025, and -$53.2 million in Q3 2025.